The Immunex Impact – Xconomy

More than any other company, Immunex made Seattle believe in the 1980s and 1990s that it could diversify its economy beyond aerospace and software to also become a world-class cluster for biotechnology. Immunex suffered some wrenching ups and downs, but ultimately delivered a breakthrough for autoimmune diseases that’s projected to be the world’s third-best-selling drug by 2014 with $8 billion in sales. The company that created that drug is long gone from Seattle, having agreed to be acquired 10 years ago this fall by Amgen. But what happened to all those people who lived the dream at Immunex, and what kind of ripple effect are they still having today in Seattle? Xconomy is bringing together some of the leading Immunex alumni for a lively evening of war stories, networking and thinking about what’s ahead for Seattle biotech.

You can register for this event online.